Limitless X Holdings Inc.
2.2000+0.03 (+1.38%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQX · LIMX · USD
Key Stats
Market Cap
37.18MP/E (TTM)
-Basic EPS (TTM)
-3.20Dividend Yield
0%Recent Filings
8-K
Preferred stock reclassification
Limitless X Holdings Inc. amended its Class C Convertible Preferred Stock designation effective September 30, 2025, stripping liquidation preferences beyond legal minimums and eliminating conversion rights tied to liquidation events. This tweak aims to reclassify the stock as permanent equity, pending auditor nod, potentially strengthening the balance sheet. Auditors will decide.
8-K
Strategic transformation and capital raise
Limitless X Holdings announced its SEC-qualified Regulation A Tier 2 offering on September 3, 2025, introducing perpetual preferred stock (LIMXP) with a 15% annual dividend to fuel growth in wellness, entertainment, and digital assets while preserving common shareholder value. The company is restructuring legacy debt, including the CEO's personal relinquishment of Series C preferred claims, to clean up its balance sheet and reduce negative equity. This positions Limitless X for expansion into AI-driven health diagnostics via BodyCor and film production through Limitless Films. Forward-looking plans target rapid revenue growth, yet risks like market acceptance loom.
10-Q
Q2 FY2025 results
Limitless X Holdings posted Q2 FY2025 revenue of $302.6M, down 78.5% y/y from $1.4M yet holding gross margins steady at 71.3% versus 70.6% last year, as cost controls offset the sales dip from shifted marketing tactics. Operating loss widened to $777K from $521K y/y, driven by higher salaries, while the six-month net loss ballooned to $39.2M from $1.7M, largely due to $33.8M in debt settlement losses from converting shareholder notes to preferred stock—far exceeding the $5.0M operating shortfall. Cash edged up to $85K on $2.0M in related-party borrowings, though free cash flow isn't disclosed in the 10-Q; total debt sits at $1.5M in short-term notes. Conversions cleaned up the balance sheet but spiked the deficit to $38.8M. Debt overhang lingers.
8-K
Related-party loan infusion
Limitless X Holdings secured a $250,000 promissory note from EM1 Capital, controlled by CEO Jaspreet Mathur, effective July 11, 2025, carrying 15% annual interest and maturing July 11, 2026, to fund working capital and growth through August 29. In exchange, the company issued 500,000 restricted common shares and warrants for another 500,000 shares at $0.80 exercise price over five years with cashless options. This related-party infusion bolsters liquidity but ties executive interests closer to repayment risks.
8-K
Insider loans fund operations
Limitless X Holdings secured $25,000 from EM1 Capital, controlled by CEO Jaspreet Mathur, via a promissory note at 15% interest maturing December 9, 2025, or upon $1M funding, earmarked for auditing fees. A second $75,000 note, with $20,000 advanced so far, carries identical terms for general expenses, plus 15,000 restricted common shares as incentive. These insider loans bridge cash needs, but default risks loom with 3% monthly penalties.
IPO
Website
Employees
Sector
Industry
BDPT
Bioadaptives, Inc.
0.03+0.00
CFOO
CHINA FOODS HOLDINGS LTD
0.66+0.00
HLF
Herbalife Ltd.
8.02-0.09
IMG
CIMG Inc.
0.24-0.01
LFVN
Lifevantage Corporation
8.15-0.36
LSF
Laird Superfood, Inc.
4.64-0.11
NAII
Natural Alternatives Internatio
2.81-0.05
NATR
Nature's Sunshine Products, Inc
13.42-0.43
NXMH
NEXT MEATS HLDGS INC.
0.01-0.01
PSYCF
Psyched Wellness Ltd.
0.01+0.00